Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

The document outlines the Department of Defense (DOD) Uniform Formulary Class review for Oncological Agents, specifically for the Myelofibrosis subclass. It details the process for a Blanket Purchase Agreement (BPA) Appendix and an Additional Discount Program (ADP) Appendix. Key dates include a P&T Committee Meeting on February 4-5, 2026, and a quote due date of January 16, 2026. The document specifies various scenarios for drug inclusion in the Uniform Formulary (UF) and outlines conditions for both before-step and after-step therapy agents, as well as uniform and non-formulary options. It also introduces a step therapy addendum with grandfathering provisions and notes that prior authorization may apply. Manufacturers are instructed to submit fully executed signature pages with their quotes, and pricing for pharmaceutical agents will be consistent across all package sizes within a given dispensing venue. The ADP section details TRICARE Retail Refund scenarios for Tier 2 and Tier 3 drugs, including how total calculated refunds are derived based on Non-FAMP and Federal Ceiling Price.

The Defense Health Agency issued Amendment HT9402-26-Q-9101 0001 on December 3, 2025, to modify solicitation HT9402-26-Q-9101. The amendment's sole purpose is to incorporate the February 2026 Pharmacy and Therapeutics (P&T) utilization reporting into the existing solicitation. All other terms and conditions of the original solicitation remain unchanged. The amendment was digitally signed by Marsha L. Petersen, Contracting Officer.

This government file, titled "Pharmacy Operations Support Contract (POSC) - February 2026 P&T Meeting Reporting," details limitations and data sets derived from the Military Health System (MHS) Pharmacy Data Transaction Service (PDTS) for the period of October 1, 2024, to September 30, 2025. The PDTS is an integrated pharmacy system primarily used for patient eligibility, safety concerns (drug interactions, dosages), and reimbursement. The document highlights the system's limitations for chronological and research functions due to continuous updates. Specific limitations include issues with unpicked-up prescriptions, changes in dispensing procedures (e.g., 90-day vs. 30-day supply), inability to differentiate acute vs. chronic use, lack of off-label use identification, and impact of mobile populations on prescription counts. The data sets provided focus on "ANTIHEMOPHILIC AGENTS SUBCLASS NON-FACTOR AGENTS" and "ONCOLOGICAL AGENTS SUBCLASS MYELOFIBROSIS," listing brand and generic names, strengths, dosage forms, manufacturers, and dispensing quantities across different service categories (retail, mail order, MTF) for various quarters.

The Defense Health Agency issued Amendment HT9402-26-Q-9101 0002 on January 7, 2026. This amendment's purpose is to remove the "Antihemophilic Agents – Non Factor Agents" class, including specific drugs like Alhemo Pen, Hemlibra, Hympavzi Pen, and Qfitlia, from the February 2026 Pharmacy & Therapeutics (P&T) review. These agents will now be reviewed during the May 2026 P&T. All other terms and conditions of the original solicitation remain unchanged. The amendment was signed by Marsha L. Petersen, Contracting Officer.

This document outlines instructions for filling out price appendices for government RFPs, specifically for Blanket Purchase Agreements (BPAs) and Average Dealer Price (ADP) submissions. For BPAs, vendors must complete yellow cells, which include package size and price per NDC, with the latter highlighting red if no quote is submitted for a condition set. The price per unit is auto-calculated. For ADP, vendors input non-FAMP and Federal Ceiling Prices, with a 0.0000% additional offered refund highlighting red if no quote is submitted. Total calculated refunds are auto-calculated. Both appendices provide tables for up to 10 NDCs; vendors needing more must contact the listed POCs. Formulary Notes in both sections offer insight into the P&T committee's decision-making process.

The Department of Defense (DoD) Defense Health Agency (DHA) has issued a Request for Quotation (RFQ) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This RFQ outlines the process for manufacturers to submit offers, including UF Blanket Purchase Agreements (BPA) for Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP), and UF Additional Discount Program (ADP) agreements for the TRICARE retail network. The DoD Pharmacy and Therapeutics (P&T) Committee will evaluate pharmaceutical agents based on clinical and cost-effectiveness to determine their placement on the UF and their cost-share tier classification (generic, formulary, or non-formulary). The RFQ details submission steps, general information, points of contact, key dates, and specific instructions for both BPA and ADP quotes, emphasizing compliance and pricing requirements. It also defines terms and acronyms relevant to the DoD's pharmacy benefits program.

The Department of Defense (DOD) Uniform Formulary Class for ANTIHEMOPHILIC AGENTS, specifically NON-FACTOR AGENTS, is undergoing review by the P&T Committee from February 4-5, 2026. Quotes for this review are due by January 16, 2026. The document outlines various scenarios for formulary status (Uniform Formulary Before-Step, After-Step, and Non-Formulary After-Step) for Military Treatment Facility and Mail Order, indicating that "NO QUOTE" has been submitted for all listed NDC numbers across these scenarios. It also details the TRICARE Retail Refund scenarios for Tier 2 (Before-Step and After-Step) and Tier 3 (After-Step) agents, with similar indications of no quotes. Key notes include the potential for Prior Authorization (PA), special reimbursement methods, consideration of preferential status for non-generic agents (Tier 1), and possible exclusion from the TRICARE pharmacy benefit program. Step Therapy with a grandfathering process is outlined, requiring new patients to trial step-preferred agents. Manufacturers are reminded to submit fully executed signature pages with quote information, and the price per unit will be consistent across package sizes for a given dosage form and strength.